Major histocompatibility complex class I-associated dinitrophenyl-modified autologous tumor peptide antigens (MHC I-DNP-tumor antigens)

Major histocompatibility complex (MHC) class I-associated dinitrophenyl (DNP)-modified autologous tumor peptide antigens represent a specialized class of therapeutic targets used in cancer immunotherapy. This approach involves the chemical conjugation of the hapten DNP to a patient's own (autologous) tumor cells, which modifies the surface proteins and internal peptides. These DNP-modified peptides are subsequently processed and presented on the cell surface by MHC class I molecules. By introducing a highly immunogenic hapten like DNP, the immune system is 'tricked' into recognizing the tumor cells as foreign, thereby overcoming the natural immune tolerance that often allows tumors to evade detection. This recognition triggers a potent cellular immune response, specifically activating CD8+ cytotoxic T-lymphocytes that can target and destroy tumor cells expressing these modified antigens. Clinical applications have primarily focused on autologous tumor cell vaccines, such as M-Vax, which have been investigated for the treatment of melanoma and other solid tumors.

Other names

DNP-modified tumor antigensDNP-modified autologous tumor cellsDNP-conjugated tumor peptidesDinitrophenyl-modified MHC-peptide complexes

The dinitrophenyl (DNP) hapten is chemically conjugated to autologous tumor cells, modifying the tumor-associated antigens. When these modified cells are administered as a vaccine, the DNP-modified peptides are presented by MHC class I molecules, making the tumor cells appear 'foreign' to the immune system. This bypasses immune tolerance and stimulates a robust CD8+ cytotoxic T-lymphocyte (CTL) response against both the modified and unmodified tumor antigens.